ExeMBA, HEALTHCARE & LIFE SCIENCES MANAGEMENT

 Issued a National Market Analysis Report for CHINA (Visited Beijing and Shanghai). The report was issued as an overall strategy to understand the healthcare system in China and key implications for Life Sciences Business. Before visiting China he worked with the Ministry of Health (USA-China) to prepare him for the trip. During his visitation he consulted private/public hospitals and visited life science-biotech companies.
 Issued Strategic and Operational Challenges for BIOCON LTD. Determined the right way to approach expansion into R&D; thoughtful risk management strategy; proper balance between sustainability, growth and viability of the current business; and leveraging India as a primary marketing strategy for the proprietary medicines business unit. Operational challenges addressed.
 Involved in the following Medical Communication areas: Communication strategy development, medical education, publication planning, opinion leader programs, scientific meetings and events, proposal development, pitches, presentations, competitive literature audits, market research, scientific reviews, developed/forecasted future product opportunities, provided commercial analysis proposals, competitive analysis and extraction (clinical trials, pipeline) and scientific slide kits. Main accounts encompassed the PFIZER/ Alzheimer’s disease/Bapineuzumab, PFIZER comprehensive Specialty Neuroscience communication plan, PFIZER/ Neuroscience monographs; PFIZER/Cardiovascular disease, including Analysis and Intelligence; BAXTER/Gammagard account, including symposia; ACTON Pharma/Aerospan (flunisolide HFA) account - Strategic direction and tactics including publications and forecasts based on new product launches.
 Understands the key concepts, processes, and tools of strategic decision-making at the business level. Feasibility, Business, Marketing and Rx-to-OTC plans are ***** petitive Strategy in the Pharmaceutical Industry is done via Environmental scan, SWOT, and Porter’s model. Premarket conditioning, rigorous scientific analysis, brand stewardship and lifecycle management.

M. Sc. - PhD, MEDICINAL CHEMISTRY

 Dynamic 15+ year career reflecting award winning performance and proven drug R&D experience.
 He remains current on cutting-edge literature developments and applies key knowledge to drive the drug discovery process. Sound knowledge of preclinical and clinical R&D and the overall drug development process.
 Expertise in Neurodegenerative diseases, CVD and Oncology
 Responsibilities include project management, project controls, staffing, contract coordination, field troubleshooting, client interface, administration, and budgeting.
 Extensive cross-functional experience in all phases of preclinical drug discovery including early hit characterization (hit to lead), lead structure-property optimization, and development-track nominations.
 He successfully has progressed projects from hit to pre-clinical candidate stage. He has developed timelines for cutting edge Neurodegenerative projects, and provided regulatory guidance to teams in order to bridge changes.

M. Sc. , CNS PHARMACOLOGY

 He involved in the following clinical operation projects: Delivered clinical pharmacology analyses and recommendations for applicability and completeness of non-clinical studies prior to new compounds entering phase I
 Participated as a key member of the clinical project teams and help to design phase I
 Communicated with non-clinical pharmacology, ADME and toxicology scientific groups and clinical functional areas including Pharmacovigilance.